Another PD-1 inhibitor, pembrolizumab, was trialed for several advanced tumors, such as renal cell cancer, melanoma, and NSCLC, which led to its approval by the FDA for treating these malignancies.371–376,382. Here, PDCD1 is linked to non-small cell lung carcinoma.